The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients
Open accessAbstract
Significance Statement: Antibody and T cell responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines are poorly reported in kidney transplant recipients (KTRs) and patients on hemodialysis (HDPs). The authors investigated the response to BNT162b2 vaccine in 45 KTRs and ten HDPs. After the second dose, 88.9% of HDPs and only 17.8% of KTRs developed anti–SARS-CoV-2 antibodies. A specific T cell response was induced in 100% of HDPs and 57.8% of KTRs. The immune response seemed influenced by the immunosuppressive regimen in KTRs, particularly tacrolimus and belatacept. These results could help to better define the strategy of vaccination in this immunocompromised population. Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in patients with ESKD, and vaccination is hoped to prevent infection. Methods: Between January 18 and February 24, 2021, 225 kidney transplant recipients (KTRs) and 45 patients on hemodialysis (HDPs) received two injections of mRNA BNT162b2 vaccine. The postvaccinal humoral and cellular response was explored in the first 45 KTRs and ten HDPs. Results: After the second dose, eight HDPs (88.9%) and eight KTRs (17.8%) developed antispike SARS-CoV-2 antibodies (P<0.001). Median titers of antibodies in responders were 1052 AU/ml (IQR, 515–2689) in HDPs and 671 AU/ml (IQR, 172–1523) in KTRs (P=0.40). Nine HDPs (100%) and 26 KTRs (57.8%) showed a specific T cell response (P=0.06) after the second injection. In responders, median numbers of spike-reactive T cells were 305 SFCs per 10 6 CD3+ T cells (IQR, 95–947) in HDPs and 212 SFCs per 10 6 CD3+ T cells (IQR, 61–330) in KTRs (P=0.40). In KTRs, the immune response to BNT162b2 seemed influenced by the immunosuppressive regimen, particularly tacrolimus or belatacept. Conclusion: Immunization with BNT162b2 seems more efficient in HDPs, indicating that vaccination should be highly recommended in these patients awaiting a transplant. However, the current vaccinal strategy for KTRs may not provide effective protection against COVID-19 and will likely need to be improved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Cited by
Sun, J., Zheng, Q., Madhira, V., Olex, A. L., Anzalone, A. J., Vinson, A., Singh, J. A., French, E., Abraham, A. G., Mathew, J., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7024 · Cited by 265
Metadata
- Authors
- Bertrand, D., Hamzaoui, M., Lemée, V., Lamulle, J., Hanoy, M., Laurent, C., Lebourg, L., Etienne, I., Lemoine, M., Le Roy, F., Nezam, D., Plantier, J.-C., Boyer, O., Guerrot, D., & Candon, S.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2021-09
- Volume
- 32
- Issue
- 9
- Pages
- 2147-2152
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W3170537423
- Cited by
- 176
- References
- 2
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients. https://app.cochat.ai/papers/10.1681/asn.2021040480
- The paper
- Bertrand, D., Hamzaoui, M., Lemée, V., Lamulle, J., Hanoy, M., Laurent, C., Lebourg, L., Etienne, I., Lemoine, M., Le Roy, F., Nezam, D., Plantier, J.-C., Boyer, O., Guerrot, D., & Candon, S. (2021). Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2021040480
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.